CompletedPhase 2NCT00795886

Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Utah
Principal Investigator
Michael Pulsipher, MD
Primary Children's Hospital
Intervention
RAPAMYCIN(drug)
Enrollment
63 enrolled
Eligibility
21 years · All sexes
Timeline
20052010

Study locations (1)

Collaborators

Children's Hospital of Philadelphia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00795886 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials